Shire Plc. Downgraded to Neutral at Credit Suisse (SHPG)
Shire Plc. (NASDAQ:SHPG) was downgraded by equities research analysts at Credit Suisse from an “outperform” rating to a “neutral” rating in a research note issued to investors on Thursday, TheFlyOnTheWall.com reports.
Shire Plc. (NASDAQ:SHPG) opened at 113.87 on Thursday. Shire Plc. has a one year low of $81.76 and a one year high of $124.96. The stock’s 50-day moving average is $116.9 and its 200-day moving average is $102.5. The company has a market cap of $20.861 billion and a P/E ratio of 35.98.
Shire Plc. (NASDAQ:SHPG) last posted its quarterly earnings results on Thursday, July 25th. The company reported $1.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.60 by $0.19. The company had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same quarter in the previous year, the company posted $1.68 earnings per share. The company’s revenue for the quarter was up 5.5% on a year-over-year basis. On average, analysts predict that Shire Plc. will post $6.85 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at JPMorgan Chase & Co. upgraded shares of Shire Plc. from a “neutral” rating to an “overweight” rating in a research note to investors on Monday, September 30th. Separately, analysts at Deutsche Bank raised their price target on shares of Shire Plc. from $123.00 to $127.00 in a research note to investors on Monday, September 23rd. They now have a “buy” rating on the stock. Finally, analysts at SunTrust reiterated a “buy” rating on shares of Shire Plc. in a research note to investors on Monday, September 16th. They now have a $125.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $122.17.
Shire plc (NASDAQ:SHPG) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.